

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Apixaban for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation

Response to consultee and commentator comments on the provisional matrix of consultees and commentators

<b>Version of matrix of consultees and commentators reviewed:</b>				
Provisional matrix of consultees and commentators sent for consultation				
<b>Summary of comments, action taken, and justification of action:</b>				
	<i>Proposal:</i>	<i>Proposal made by:</i>	<i>Action taken:</i> Removed/Added/Not included/Noted	<i>Justification:</i>
1.	British Association for Nursing in Cardiac Care' should be amended to 'British Association for Nursing in Cardiovascular Care'. The former is the old name for BANCC.	British Association for Nursing in Cardiovascular Care	Amended	British Association for Nursing in Cardiac Care has been amended to British Association for Nursing in Cardiovascular Care.
2.	Heart Disease and Diabetes Research Trust	Heart Disease and Diabetes Research Trust	Removed	This organisation is no longer in operation and has been removed from all matrices as a commentator under 'research groups'.

3.	Grown up Congenital Heart Patients Association	NICE secretariat – PPIP		Added	This organisation has an interest directly related to this appraisal. They have been added to the patient / carer group under consultees.
4.	Alliance Pharmaceuticals Aspar Pharmaceuticals Dexcel Pharmaceuticals Focus Pharmaceuticals Galpharm international Greenfield Pharmaceuticals Genus Pharmaceuticals Reckitt Benckiser Thornton and Ross Wockhardt UK	NICE secretariat		Removed	These organisations do not have an area of interest directly related to this appraisal and do not meet the selection criteria to participate in this appraisal. Therefore they have been removed from the matrix as aspirin is no longer listed as a comparator.
5.	Aspirin should be removed from the brackets following comparator manufacturers that produce both aspirin and warfarin, as aspirin is no longer a comparator.	NICE secretariat		Amended	
6.	Arrow Generics Actavis UK Kent Pharmaceuticals Mylan UK	NICE secretariat		Removed	These organisations do not have an area of interest directly related to this appraisal and no longer fulfil the criteria for inclusion: Therefore Arrow Generics, Actavis UK, Kent Pharmaceuticals and Mylan UK have been removed from the matrix under 'comparator manufacturers'.

7.	Winthrop Pharmaceuticals has been acquired by Zentiva.	NICE secretariat		Amended	
8.	Goldshield Pharmaceuticals.	NICE secretariat		Amended	This organisation has been rebranded as Mercury Pharma and the amendment has been made under 'comparator manufacturers'.
9.	Rosemont Pharmaceuticals and Taro Pharmaceuticals	NICE secretariat		Added	These organisations have an area of interest directly related to this appraisal topic and meet the selection criteria to participate in this appraisal. Rosemont Pharmaceuticals and Taro Pharmaceuticals have been added to the matrix under 'comparator manufacturers'.